tegoprazan + amoxicillin + clarithromycin

Tegoprazan + amoxicillin + clarithromycin is a triple therapy regimen used primarily for the eradication of Helicobacter pylori infection. Tegoprazan is a novel potassium-competitive acid blocker (P-CAB) that inhibits gastric H+/K+-ATPase, leading to potent and sustained suppression of gastric acid secretion. Amoxicillin is a penicillin-class beta-lactam antibiotic that inhibits bacterial cell wall synthesis. Clarithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. The combination leverages tegoprazan’s strong acid suppression to enhance the efficacy of antibiotics against H. pylori in the acidic environment of the stomach[1][2][3][4][5][6]. This regimen has been shown in clinical trials to be well tolerated and effective at maintaining high intragastric pH levels, which supports improved eradication rates compared with traditional proton pump inhibitor-based therapies[2][4].

Brand names

K-CAB triple therapy

Other names

tegoprazan-based triple therapy